SCTL: An underappreciated opportunity in CDMOs – Initiating Coverage
By Beth Senko, CFA
NASDAQ:SCTL
READ THE FULL SCTL RESEARCH REPORT
Morgan Stanley Maintains Overweight on Catalent, Lowers Price Target to $132
Morgan Stanley analyst Tejas Savant maintains Catalent (NYSE:CTLT) with a Overweight and lowers the price target from $145 to $132.
Keybanc Maintains Overweight on Catalent, Lowers Price Target to $125
Keybanc analyst Paul Knight maintains Catalent (NYSE:CTLT) with a Overweight and lowers the price target from $155 to $125.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
Catalent Inc (NYSE:CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging…
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Why Erytech Pharma Are Shares Moving Higher Today
Erytech Pharma SA (NASDAQ:ERYP) has sold its US manufacturing facility to Catalent Inc (NYSE:CTLT) for $44.5 million. Catalent will acquire Erytech’s commercial-scale…
How To Attend Catalent Q3 2022 Earnings Conference Call
Catalent (NYSE:CTLT) will host a conference call at 08:15 AM ET on May 3, 2022, to discuss Q3 2022 earnings results.
How to Attend Catalent (CTLT) Conference Call
Follow this link to access the live webcast.